A carregar...

Renal outcomes of radioligand therapy: experience of (177)lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer

BACKGROUND: Radioligand therapy (RLT) with (177)lutetium (Lu)-labelled prostate-specific membrane antigen (PSMA) ligands has been increasingly used in recent years for therapy of metastatic castrate-resistant prostate cancer (mCRPC). Studies have revealed that (177)Lu-PSMA ligand therapy is well tol...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Kidney J
Main Authors: Gallyamov, Marat, Meyrick, Danielle, Barley, Jerome, Lenzo, Nat
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7769531/
https://ncbi.nlm.nih.gov/pubmed/33391748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfz101
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!